Skip to main content
Erschienen in: Breast Cancer Research 1/2012

01.02.2012 | Review

Understanding the mechanisms of aromatase inhibitor resistance

verfasst von: William R Miller, Alexey A Larionov

Erschienen in: Breast Cancer Research | Ausgabe 1/2012

Einloggen, um Zugang zu erhalten

Abstract

Aromatase inhibitors (AIs) have a central role in the treatment of breast cancer; however, resistance is a major obstacle to optimal management. Evidence from endocrine, molecular and pathological measurements in clinical material taken before and after therapy with AIs and data from clinical trials in which AIs have been given as treatment either alone or in combination with other targeted agents suggest diverse causes for resistance. These include inherent tumour insensitivity to oestrogen, ineffective inhibition of aromatase, sources of oestrogenic hormones independent of aromatase, activation of signalling by non-endocrine pathways, enhanced cell survival and selection of hormone-insensitive cellular clones during treatment.
Anhänge
Nur mit Berechtigung zugänglich
Literatur
1.
Zurück zum Zitat Winer EP, Hudis C, Burstein HJ, Wolff AC, Pritchard KI, Ingle JN, Chlebowski RT, Gelber R, Edge SB, Gralow J, Cobleigh MA, Mamounas EP, Goldstein LJ, Whelan TJ, Powles TJ, Bryant J, Perkins C, Perotti J, Braun S, Langer AS, Browman GP, Somerfield MR: American Society of Clinical Oncology technology assessment on the use of aromatase inhibitors as adjuvant therapy for postmenopausal women with hormone receptor-positive breast cancer: status report 2004. J Clin Oncol. 2005, 23: 619-629.CrossRefPubMed Winer EP, Hudis C, Burstein HJ, Wolff AC, Pritchard KI, Ingle JN, Chlebowski RT, Gelber R, Edge SB, Gralow J, Cobleigh MA, Mamounas EP, Goldstein LJ, Whelan TJ, Powles TJ, Bryant J, Perkins C, Perotti J, Braun S, Langer AS, Browman GP, Somerfield MR: American Society of Clinical Oncology technology assessment on the use of aromatase inhibitors as adjuvant therapy for postmenopausal women with hormone receptor-positive breast cancer: status report 2004. J Clin Oncol. 2005, 23: 619-629.CrossRefPubMed
2.
Zurück zum Zitat Miller WR: Aromatase inhibitors and breast cancer. Minerva Endocrinol. 2006, 31: 27-46.PubMed Miller WR: Aromatase inhibitors and breast cancer. Minerva Endocrinol. 2006, 31: 27-46.PubMed
3.
Zurück zum Zitat Lonning PE: Pharmacology of new aromatase inhibitors. Breast. 1996, 5: 202-206. 10.1016/S0960-9776(96)90094-6.CrossRef Lonning PE: Pharmacology of new aromatase inhibitors. Breast. 1996, 5: 202-206. 10.1016/S0960-9776(96)90094-6.CrossRef
4.
Zurück zum Zitat Geisler J, Haynes B, Anker G, Dowsett M, Lønning PE: Influence of letrozole and anastrozole on total body aromatization and plasma estrogen levels in postmenopausal breast cancer patients evaluated in a randomized, cross-over study. J Clin Oncol. 2002, 20: 751-757. 10.1200/JCO.20.3.751.CrossRefPubMed Geisler J, Haynes B, Anker G, Dowsett M, Lønning PE: Influence of letrozole and anastrozole on total body aromatization and plasma estrogen levels in postmenopausal breast cancer patients evaluated in a randomized, cross-over study. J Clin Oncol. 2002, 20: 751-757. 10.1200/JCO.20.3.751.CrossRefPubMed
5.
Zurück zum Zitat Dowsett M: Preoperative models to evaluate endocrine strategies for breast cancer. Clin Cancer Res. 2003, 9: 502S-510S.PubMed Dowsett M: Preoperative models to evaluate endocrine strategies for breast cancer. Clin Cancer Res. 2003, 9: 502S-510S.PubMed
6.
Zurück zum Zitat Anderson TJ, Dixon JM, Stuart M, Sahmoud T, Miller WR: Effect of neoadjuvant treatment with anastrozole on tumour histology in postmenopausal women with large operable breast cancer. Br J Cancer. 2002, 87: 334-338. 10.1038/sj.bjc.6600435.CrossRefPubMedPubMedCentral Anderson TJ, Dixon JM, Stuart M, Sahmoud T, Miller WR: Effect of neoadjuvant treatment with anastrozole on tumour histology in postmenopausal women with large operable breast cancer. Br J Cancer. 2002, 87: 334-338. 10.1038/sj.bjc.6600435.CrossRefPubMedPubMedCentral
7.
Zurück zum Zitat Dixon JM: Neoadjuvant therapy: surgical perspectives. Endocrine Therapy in Breast Cancer. Edited by: Miller WR, Ingle JN. 2002, New York: Marcel Dekker, 197-212.CrossRef Dixon JM: Neoadjuvant therapy: surgical perspectives. Endocrine Therapy in Breast Cancer. Edited by: Miller WR, Ingle JN. 2002, New York: Marcel Dekker, 197-212.CrossRef
8.
Zurück zum Zitat Miller WR, Jackson J: The therapeutic potential of aromatase inhibitors. Expert Opin Investig Drugs. 2003, 12: 1-12. 10.1517/13543784.12.1.1.CrossRef Miller WR, Jackson J: The therapeutic potential of aromatase inhibitors. Expert Opin Investig Drugs. 2003, 12: 1-12. 10.1517/13543784.12.1.1.CrossRef
9.
Zurück zum Zitat Eiermann W, Paepke S, Appfelstaedt J, Llombart-Cussac A, Eremin J, Vinholes J, Mauriac L, Ellis M, Lassus M, Chaudri-Ross HA, Dugan M, Borgs M, Letrozole Neo-Adjuvant Breast Cancer Study Group: Preoperative treatment of postmenopausal breast cancer patients with letrozole: a randomized double-blind multicenter study. Ann Oncol. 2001, 12: 1527-1532. 10.1023/A:1013128213451.CrossRefPubMed Eiermann W, Paepke S, Appfelstaedt J, Llombart-Cussac A, Eremin J, Vinholes J, Mauriac L, Ellis M, Lassus M, Chaudri-Ross HA, Dugan M, Borgs M, Letrozole Neo-Adjuvant Breast Cancer Study Group: Preoperative treatment of postmenopausal breast cancer patients with letrozole: a randomized double-blind multicenter study. Ann Oncol. 2001, 12: 1527-1532. 10.1023/A:1013128213451.CrossRefPubMed
10.
Zurück zum Zitat Smith IE, Dowsett M, Ebbs SR, Dixon JM, Skene A, Blohmer JU, Ashley SE, Francis S, Boeddinghaus I, Walsh G, IMPACT Trialists Group: Neoadjuvant treatment of postmenopausal breast cancer with anastrozole, tamoxifen, or both in combination: the Immediate Preoperative Anastrozole, Tamoxifen, or Combined with Tamoxifen (IMPACT) multicenter double-blind randomized trial. J Clin Oncol. 2005, 23: 5108-5116. 10.1200/JCO.2005.04.005.CrossRefPubMed Smith IE, Dowsett M, Ebbs SR, Dixon JM, Skene A, Blohmer JU, Ashley SE, Francis S, Boeddinghaus I, Walsh G, IMPACT Trialists Group: Neoadjuvant treatment of postmenopausal breast cancer with anastrozole, tamoxifen, or both in combination: the Immediate Preoperative Anastrozole, Tamoxifen, or Combined with Tamoxifen (IMPACT) multicenter double-blind randomized trial. J Clin Oncol. 2005, 23: 5108-5116. 10.1200/JCO.2005.04.005.CrossRefPubMed
11.
Zurück zum Zitat Mouridsen H, Gershanovich M, Sun Y, Perez-Carrion R, Boni C, Monnier A, Apffelstaedt J, Smith R, Sleeboom HP, Jaenicke F, Pluzanska A, Dank M, Becquart D, Bapsy PP, Salminen E, Snyder R, Chaudri-Ross H, Lang R, Wyld P, Bhatnagar A: Phase III study of letrozole versus tamoxifen as first-line therapy of advanced breast cancer in postmenopausal women: analysis of survival and update of efficacy from the International Letrozole Breast Cancer Group. J Clin Oncol. 2003, 21: 2101-2109. 10.1200/JCO.2003.04.194.CrossRefPubMed Mouridsen H, Gershanovich M, Sun Y, Perez-Carrion R, Boni C, Monnier A, Apffelstaedt J, Smith R, Sleeboom HP, Jaenicke F, Pluzanska A, Dank M, Becquart D, Bapsy PP, Salminen E, Snyder R, Chaudri-Ross H, Lang R, Wyld P, Bhatnagar A: Phase III study of letrozole versus tamoxifen as first-line therapy of advanced breast cancer in postmenopausal women: analysis of survival and update of efficacy from the International Letrozole Breast Cancer Group. J Clin Oncol. 2003, 21: 2101-2109. 10.1200/JCO.2003.04.194.CrossRefPubMed
12.
Zurück zum Zitat Johnston SR, Martin LA, Head J, Smith I, Dowsett M: Aromatase inhibitors: combinations with fulvestrant or signal transduction inhibitors as a strategy to overcome endocrine resistance. J Steroid Biochem Mol Biol. 2005, 95: 173-181. 10.1016/j.jsbmb.2005.04.004.CrossRefPubMed Johnston SR, Martin LA, Head J, Smith I, Dowsett M: Aromatase inhibitors: combinations with fulvestrant or signal transduction inhibitors as a strategy to overcome endocrine resistance. J Steroid Biochem Mol Biol. 2005, 95: 173-181. 10.1016/j.jsbmb.2005.04.004.CrossRefPubMed
13.
Zurück zum Zitat Miller WR, Larionov A: Changes in expression of oestrogen regulated and proliferation genes with neoadjuvant treatment highlight heterogeneity of clinical resistance to the aromatase inhibitor, letrozole. Breast Cancer Res. 2010, 12: R52-10.1186/bcr2611.CrossRefPubMedPubMedCentral Miller WR, Larionov A: Changes in expression of oestrogen regulated and proliferation genes with neoadjuvant treatment highlight heterogeneity of clinical resistance to the aromatase inhibitor, letrozole. Breast Cancer Res. 2010, 12: R52-10.1186/bcr2611.CrossRefPubMedPubMedCentral
14.
Zurück zum Zitat Miller WR, White S, Dixon JM, Murray J, Renshaw L, Anderson TJ: Proliferation, steroid receptors and clinical/pathological response in breast cancer treated with letrozole. Br J Cancer. 2006, 94: 1051-1056. 10.1038/sj.bjc.6603001.CrossRefPubMedPubMedCentral Miller WR, White S, Dixon JM, Murray J, Renshaw L, Anderson TJ: Proliferation, steroid receptors and clinical/pathological response in breast cancer treated with letrozole. Br J Cancer. 2006, 94: 1051-1056. 10.1038/sj.bjc.6603001.CrossRefPubMedPubMedCentral
15.
Zurück zum Zitat Miller WR, Larionov AA, Renshaw L, Anderson TJ, White S, Murray J, Murray E, Hampton G, Walker JR, Ho S, Krause A, Evans DB, Dixon JM: Changes in breast cancer transcriptional profiles after treatment with the aromatase inhibitor, letrozole. Pharmacogenet Genomics. 2007, 17: 813-826. 10.1097/FPC.0b013e32820b853a.CrossRefPubMed Miller WR, Larionov AA, Renshaw L, Anderson TJ, White S, Murray J, Murray E, Hampton G, Walker JR, Ho S, Krause A, Evans DB, Dixon JM: Changes in breast cancer transcriptional profiles after treatment with the aromatase inhibitor, letrozole. Pharmacogenet Genomics. 2007, 17: 813-826. 10.1097/FPC.0b013e32820b853a.CrossRefPubMed
16.
Zurück zum Zitat Mackay A, Urruticoechea A, Dixon JM, Dexter T, Fenwick K, Ashworth A, Drury S, Larionov A, Young O, White S, Miller WR, Evans DB, Dowsett M: Molecular response to aromatase inhibitor treatment in primary breast cancer. Breast Cancer Res. 2007, 9: R37-10.1186/bcr1732.CrossRefPubMedPubMedCentral Mackay A, Urruticoechea A, Dixon JM, Dexter T, Fenwick K, Ashworth A, Drury S, Larionov A, Young O, White S, Miller WR, Evans DB, Dowsett M: Molecular response to aromatase inhibitor treatment in primary breast cancer. Breast Cancer Res. 2007, 9: R37-10.1186/bcr1732.CrossRefPubMedPubMedCentral
17.
Zurück zum Zitat Geisler J, Lonning PE: Resistance to endocrine therapy of breast cancer: recent advances and tomorrow's challenges. Clin Breast Cancer. 2001, 1: 297-308. 10.3816/CBC.2001.n.004.CrossRefPubMed Geisler J, Lonning PE: Resistance to endocrine therapy of breast cancer: recent advances and tomorrow's challenges. Clin Breast Cancer. 2001, 1: 297-308. 10.3816/CBC.2001.n.004.CrossRefPubMed
18.
Zurück zum Zitat Perey L, Paridaens R, Hawle H, Zaman K, Nolé F, Wildiers H, Fiche M, Dietrich D, Clément P, Köberle D, Goldhirsch A, Thürlimann B: Clinical benefit of fulvestrant in postmenopausal women with advanced breast cancer and primary or acquired resistance to aromatase inhibitors: final results of phase II Swiss Group for Clinical Cancer Research Trial (SAKK 21/00). Ann Oncol. 2007, 18: 64-69.CrossRefPubMed Perey L, Paridaens R, Hawle H, Zaman K, Nolé F, Wildiers H, Fiche M, Dietrich D, Clément P, Köberle D, Goldhirsch A, Thürlimann B: Clinical benefit of fulvestrant in postmenopausal women with advanced breast cancer and primary or acquired resistance to aromatase inhibitors: final results of phase II Swiss Group for Clinical Cancer Research Trial (SAKK 21/00). Ann Oncol. 2007, 18: 64-69.CrossRefPubMed
20.
Zurück zum Zitat Lonning PE: Lack of complete cross-resistance between different aromatase inhibitors; a real finding in search for an explanation?. Eur J Cancer. 2009, 45: 527-535. 10.1016/j.ejca.2008.10.019.CrossRefPubMed Lonning PE: Lack of complete cross-resistance between different aromatase inhibitors; a real finding in search for an explanation?. Eur J Cancer. 2009, 45: 527-535. 10.1016/j.ejca.2008.10.019.CrossRefPubMed
21.
Zurück zum Zitat Beresford M, Tumur I, Chakrabarti J, Barden J, Rao N, Makris A: A qualitative systematic review of the evidence base for non-cross-resistance between steroidal and non-steroidal aromatase inhibitors in metastatic breast cancer. Clin Oncol (R Coll Radiol). 2011, 23: 209-215. 10.1016/j.clon.2010.11.005.CrossRef Beresford M, Tumur I, Chakrabarti J, Barden J, Rao N, Makris A: A qualitative systematic review of the evidence base for non-cross-resistance between steroidal and non-steroidal aromatase inhibitors in metastatic breast cancer. Clin Oncol (R Coll Radiol). 2011, 23: 209-215. 10.1016/j.clon.2010.11.005.CrossRef
22.
Zurück zum Zitat Paridaens RJ, Dirix LY, Beex LV, Nooij M, Cameron DA, Cufer T, Piccart MJ, Bogaerts J, Therasse P: Phase III study comparing exemestane with tamoxifen as first-line hormonal treatment of metastatic breast cancer in postmenopausal women: the european organisation for research and treatment of cancer breast cancer cooperative group. Ann Oncol. 2003, 14: 1391-1398. 10.1093/annonc/mdg362.CrossRefPubMed Paridaens RJ, Dirix LY, Beex LV, Nooij M, Cameron DA, Cufer T, Piccart MJ, Bogaerts J, Therasse P: Phase III study comparing exemestane with tamoxifen as first-line hormonal treatment of metastatic breast cancer in postmenopausal women: the european organisation for research and treatment of cancer breast cancer cooperative group. Ann Oncol. 2003, 14: 1391-1398. 10.1093/annonc/mdg362.CrossRefPubMed
23.
Zurück zum Zitat Ellis MJ, Coop A, Singh B, Mauriac L, Llombert-Cussac A, Jänicke F, Miller WR, Evans DB, Dugan M, Brady C, Quebe-Fehling E, Borgs M: Letrozole is more effective neoadjuvant endocrine therapy than tamoxifen for ErbB-1- and/or ErbB-2-positive, estrogen receptor-positive primary breast cancer: evidence from a phase III randomized trial. J Clin Oncol. 2001, 19: 3808-3816.PubMed Ellis MJ, Coop A, Singh B, Mauriac L, Llombert-Cussac A, Jänicke F, Miller WR, Evans DB, Dugan M, Brady C, Quebe-Fehling E, Borgs M: Letrozole is more effective neoadjuvant endocrine therapy than tamoxifen for ErbB-1- and/or ErbB-2-positive, estrogen receptor-positive primary breast cancer: evidence from a phase III randomized trial. J Clin Oncol. 2001, 19: 3808-3816.PubMed
24.
Zurück zum Zitat Ingle JN, Johnson PA, Suman VJ, Gerstner JB, Mailliard JA, Camoriano JK, Gesme DH, Loprinzi CL, Hatfi eld AK, Hartmann LC: A randomized phase II trial of two dosage levels of letrozole as third-line hormonal therapy for women with metastatic breast carcinoma. Cancer. 1997, 80: 218-224. 10.1002/(SICI)1097-0142(19970715)80:2<218::AID-CNCR8>3.0.CO;2-P.CrossRefPubMed Ingle JN, Johnson PA, Suman VJ, Gerstner JB, Mailliard JA, Camoriano JK, Gesme DH, Loprinzi CL, Hatfi eld AK, Hartmann LC: A randomized phase II trial of two dosage levels of letrozole as third-line hormonal therapy for women with metastatic breast carcinoma. Cancer. 1997, 80: 218-224. 10.1002/(SICI)1097-0142(19970715)80:2<218::AID-CNCR8>3.0.CO;2-P.CrossRefPubMed
25.
Zurück zum Zitat Jones S, Vogel C, Arkhipov A, Fehrenbacher L, Eisenberg P, Cooper B, Honig S, Polli A, Whaley F, di Salle E, Tiffany J, Consonni A, Miller L: Multicenter, Phase II trial of exemestane as third-line hormonal therapy of postmenopausal women with metastatic breast cancer. J Clin Oncol. 1999, 17: 3418-3425.PubMed Jones S, Vogel C, Arkhipov A, Fehrenbacher L, Eisenberg P, Cooper B, Honig S, Polli A, Whaley F, di Salle E, Tiffany J, Consonni A, Miller L: Multicenter, Phase II trial of exemestane as third-line hormonal therapy of postmenopausal women with metastatic breast cancer. J Clin Oncol. 1999, 17: 3418-3425.PubMed
26.
Zurück zum Zitat Rose C: A comparison of the efficacy of aromatase inhibitors in second-line treatment of metastatic breast cancer. Am J Clin Oncol. 2003, 26 (suppl 1): S9-S16.CrossRefPubMed Rose C: A comparison of the efficacy of aromatase inhibitors in second-line treatment of metastatic breast cancer. Am J Clin Oncol. 2003, 26 (suppl 1): S9-S16.CrossRefPubMed
27.
Zurück zum Zitat Paepke S, Tulusan A, Kiesel L, Bastert G, Jaenicke FK, Bouterfa H, Wackwitz B: A multi-center study of pre-operative treatment with letrozole for optimal duration of treatment in postmenopausal women with ER and/or PgR positive breast cancer. Proc Am Soc Clin Oncol. 2003, Abstract 321- Paepke S, Tulusan A, Kiesel L, Bastert G, Jaenicke FK, Bouterfa H, Wackwitz B: A multi-center study of pre-operative treatment with letrozole for optimal duration of treatment in postmenopausal women with ER and/or PgR positive breast cancer. Proc Am Soc Clin Oncol. 2003, Abstract 321-
28.
Zurück zum Zitat Dixon JM, Renshaw L, Macaskill EJ, Young O, Murray J, Cameron D, Kerr GR, Evans DB, Miller WR: Increase in response rate by prolonged treatment with neoadjuvant letrozole. Breast Cancer Res Treat. 2009, 113: 145-151. 10.1007/s10549-008-9915-6.CrossRefPubMed Dixon JM, Renshaw L, Macaskill EJ, Young O, Murray J, Cameron D, Kerr GR, Evans DB, Miller WR: Increase in response rate by prolonged treatment with neoadjuvant letrozole. Breast Cancer Res Treat. 2009, 113: 145-151. 10.1007/s10549-008-9915-6.CrossRefPubMed
29.
Zurück zum Zitat Baselga J, Semiglazov V, van Dam P, Manikhas A, Bellet M, Mayordomo J, Campone M, Kubista E, Greil R, Bianchi G, Steinseifer J, Molloy B, Tokaji E, Gardner H, Phillips P, Stumm M, Lane HA, Dixon JM, Jonat W, Hope S: Phase II randomized study of neoadjuvant everolimus plus letrozole compared with placebo plus letrozole in patients with estrogen receptor-positive breast cancer. J Clin Oncol. 2009, 27: 2630-2637. 10.1200/JCO.2008.18.8391.CrossRefPubMed Baselga J, Semiglazov V, van Dam P, Manikhas A, Bellet M, Mayordomo J, Campone M, Kubista E, Greil R, Bianchi G, Steinseifer J, Molloy B, Tokaji E, Gardner H, Phillips P, Stumm M, Lane HA, Dixon JM, Jonat W, Hope S: Phase II randomized study of neoadjuvant everolimus plus letrozole compared with placebo plus letrozole in patients with estrogen receptor-positive breast cancer. J Clin Oncol. 2009, 27: 2630-2637. 10.1200/JCO.2008.18.8391.CrossRefPubMed
30.
Zurück zum Zitat Cristofanilli M, Valero V, Mangalik A, Royce M, Rabinowitz I, Arena FP, Kroener JF, Curcio E, Watkins C, Bacus S, Cora EM, Anderson E, Magill PJ: Phase II, randomized trial to compare anastrozole combined with gefitinib or placebo in postmenopausal women with hormone receptor-positive metastatic breast cancer. Clin Cancer Res. 2010, 16: 1904-1914. 10.1158/1078-0432.CCR-09-2282.CrossRefPubMed Cristofanilli M, Valero V, Mangalik A, Royce M, Rabinowitz I, Arena FP, Kroener JF, Curcio E, Watkins C, Bacus S, Cora EM, Anderson E, Magill PJ: Phase II, randomized trial to compare anastrozole combined with gefitinib or placebo in postmenopausal women with hormone receptor-positive metastatic breast cancer. Clin Cancer Res. 2010, 16: 1904-1914. 10.1158/1078-0432.CCR-09-2282.CrossRefPubMed
31.
Zurück zum Zitat Smith IE, Walsh G, Skene A, Llombart A, Mayordom JI, Detre S, Salter J, Clark E, Magill P, Dowsett M: A phase II placebo-controlled trial of neoadjuvant anastrozole alone or with gefitinib in early breast cancer. J Clin Oncol. 2007, 25: 3816-3822. 10.1200/JCO.2006.09.6578.CrossRefPubMed Smith IE, Walsh G, Skene A, Llombart A, Mayordom JI, Detre S, Salter J, Clark E, Magill P, Dowsett M: A phase II placebo-controlled trial of neoadjuvant anastrozole alone or with gefitinib in early breast cancer. J Clin Oncol. 2007, 25: 3816-3822. 10.1200/JCO.2006.09.6578.CrossRefPubMed
32.
Zurück zum Zitat Johnston S, Pippen J, Pivot X, Lichinitser M, Sadeghi S, Dieras V, Gomez HL, Romieu G, Manikha A, Kennedy MJ, Press MF, Maltzman J, Florance A, O'Rourke L, Oliva C, Stein S, Pegram M: Lapatinib combined with letrozole versus letrozole and placebo as first-line therapy for postmenopausal hormone receptor-positive metastatic breast cancer. J Clin Oncol. 2009, 27: 5538-5546. 10.1200/JCO.2009.23.3734.CrossRefPubMed Johnston S, Pippen J, Pivot X, Lichinitser M, Sadeghi S, Dieras V, Gomez HL, Romieu G, Manikha A, Kennedy MJ, Press MF, Maltzman J, Florance A, O'Rourke L, Oliva C, Stein S, Pegram M: Lapatinib combined with letrozole versus letrozole and placebo as first-line therapy for postmenopausal hormone receptor-positive metastatic breast cancer. J Clin Oncol. 2009, 27: 5538-5546. 10.1200/JCO.2009.23.3734.CrossRefPubMed
33.
Zurück zum Zitat Kaufman B, Mackey JR, Clemens MR, Bapsy PP, Vaid A, Wardley A, Tjulandin S, Jahn M, Lehle M, Feyereislova A, Révil C, Jones A: Trastuzumab plus anastrozole versus anastrozole alone for the treatment of postmenopausal women with human epidermal growth factor receptor 2-positive, hormone receptor-positive metastatic breast cancer: results from the randomized Phase III TAnDEM Study. J Clin Oncol. 2009, 27: 5529-5537. 10.1200/JCO.2008.20.6847.CrossRefPubMed Kaufman B, Mackey JR, Clemens MR, Bapsy PP, Vaid A, Wardley A, Tjulandin S, Jahn M, Lehle M, Feyereislova A, Révil C, Jones A: Trastuzumab plus anastrozole versus anastrozole alone for the treatment of postmenopausal women with human epidermal growth factor receptor 2-positive, hormone receptor-positive metastatic breast cancer: results from the randomized Phase III TAnDEM Study. J Clin Oncol. 2009, 27: 5529-5537. 10.1200/JCO.2008.20.6847.CrossRefPubMed
34.
Zurück zum Zitat Murray R, Pitt P: Aromatase inhibition with 4-OHAndrostenedione after prior aromatase inhibition with aminoglutethimide in women with advanced breast cancer. Breast Cancer Res Treat. 1995, 35: 249-253. 10.1007/BF00665976.CrossRefPubMed Murray R, Pitt P: Aromatase inhibition with 4-OHAndrostenedione after prior aromatase inhibition with aminoglutethimide in women with advanced breast cancer. Breast Cancer Res Treat. 1995, 35: 249-253. 10.1007/BF00665976.CrossRefPubMed
35.
Zurück zum Zitat Geisler J, Johannessen DC, Anker G, Lønning PE: Treatment with formestane alone and in combination with aminoglutethimide in heavily pretreated breast cancer patients: Clinical and endocrine effects. Eur J Cancer. 1996, 32A: 789-792. 10.1016/0959-8049(95)00623-0.CrossRefPubMed Geisler J, Johannessen DC, Anker G, Lønning PE: Treatment with formestane alone and in combination with aminoglutethimide in heavily pretreated breast cancer patients: Clinical and endocrine effects. Eur J Cancer. 1996, 32A: 789-792. 10.1016/0959-8049(95)00623-0.CrossRefPubMed
36.
Zurück zum Zitat Lønning PE, Bajetta E, Murray R, Tubiana-Hulin M, Eisenberg PD, Mickiewicz E, Celio L, Pitt P, Mita M, Aaronson NK, Fowst C, Arkhipov A, di Salle E, Polli A, Massimini G: Activity of exemestane in metastatic breast cancer after failure of nonsteroidal aromatase inhibitors: a phase II trial. J Clin Oncol. 2000, 18: 2234-2244.PubMed Lønning PE, Bajetta E, Murray R, Tubiana-Hulin M, Eisenberg PD, Mickiewicz E, Celio L, Pitt P, Mita M, Aaronson NK, Fowst C, Arkhipov A, di Salle E, Polli A, Massimini G: Activity of exemestane in metastatic breast cancer after failure of nonsteroidal aromatase inhibitors: a phase II trial. J Clin Oncol. 2000, 18: 2234-2244.PubMed
37.
Zurück zum Zitat Bertelli G, Garrone O, Merlano M, Occelli M, Bertolotti L, Castiglione F, Pepi F, Fusco O, Del Mastro L, Leonard RC: Sequential treatment with exemestane and non-steroidal aromatase inhibitors in advanced breast cancer. Oncology. 2005, 69: 471-477. 10.1159/000090985.CrossRefPubMed Bertelli G, Garrone O, Merlano M, Occelli M, Bertolotti L, Castiglione F, Pepi F, Fusco O, Del Mastro L, Leonard RC: Sequential treatment with exemestane and non-steroidal aromatase inhibitors in advanced breast cancer. Oncology. 2005, 69: 471-477. 10.1159/000090985.CrossRefPubMed
38.
Zurück zum Zitat Miller WR, Bartlett J, Brodie AM, Brueggemeier RW, di Salle E, Lønning PE, Llombart A, Maass N, Maudelonde T, Sasano H, Goss PE: Aromatase inhibitors: are there differences between steroidal and nonsteroidal aromatase inhibitors and do they matter?. Oncologist. 2008, 13: 829-837. 10.1634/theoncologist.2008-0055.CrossRefPubMed Miller WR, Bartlett J, Brodie AM, Brueggemeier RW, di Salle E, Lønning PE, Llombart A, Maass N, Maudelonde T, Sasano H, Goss PE: Aromatase inhibitors: are there differences between steroidal and nonsteroidal aromatase inhibitors and do they matter?. Oncologist. 2008, 13: 829-837. 10.1634/theoncologist.2008-0055.CrossRefPubMed
39.
Zurück zum Zitat Chia S, Gradishar W, Mauriac L, Bines J, Amant F, Federico M, Fein L, Romieu G, Buzdar A, Robertson JF, Brufsky A, Possinger K, Rennie P, Sapunar F, Lowe E, Piccart M: Double-blind, randomized placebo controlled trial of fulvestrant compared with exemestane after prior nonsteroidal aromatase inhibitor therapy in postmenopausal women with hormone receptor-positive, advanced breast cancer: results from EFECT. J Clin Oncol. 2008, 26: 1664-1670. 10.1200/JCO.2007.13.5822.CrossRefPubMed Chia S, Gradishar W, Mauriac L, Bines J, Amant F, Federico M, Fein L, Romieu G, Buzdar A, Robertson JF, Brufsky A, Possinger K, Rennie P, Sapunar F, Lowe E, Piccart M: Double-blind, randomized placebo controlled trial of fulvestrant compared with exemestane after prior nonsteroidal aromatase inhibitor therapy in postmenopausal women with hormone receptor-positive, advanced breast cancer: results from EFECT. J Clin Oncol. 2008, 26: 1664-1670. 10.1200/JCO.2007.13.5822.CrossRefPubMed
40.
Zurück zum Zitat Bunone G, Briand PA, Miksicek RJ, Picard D: Activation of the unliganded estrogen receptor by EGF involves the MAP kinase pathway and direct phosphorylation. EMBO J. 1996, 15: 2174-2183.PubMedPubMedCentral Bunone G, Briand PA, Miksicek RJ, Picard D: Activation of the unliganded estrogen receptor by EGF involves the MAP kinase pathway and direct phosphorylation. EMBO J. 1996, 15: 2174-2183.PubMedPubMedCentral
41.
Zurück zum Zitat Ellis MJ, Tao Y, Young O, White S, Proia AD, Murray J, Renshaw L, Faratian D, Thomas J, Dowsett M, Krause A, Evans DB, Miller WR, Dixon JM: Estrogen-independent proliferation is present in estrogen-receptor HER2-positive primary breast cancer after neoadjuvant letrozole. J Clin Oncol. 2006, 24: 3019-3025. 10.1200/JCO.2005.04.3034.CrossRefPubMed Ellis MJ, Tao Y, Young O, White S, Proia AD, Murray J, Renshaw L, Faratian D, Thomas J, Dowsett M, Krause A, Evans DB, Miller WR, Dixon JM: Estrogen-independent proliferation is present in estrogen-receptor HER2-positive primary breast cancer after neoadjuvant letrozole. J Clin Oncol. 2006, 24: 3019-3025. 10.1200/JCO.2005.04.3034.CrossRefPubMed
42.
Zurück zum Zitat Dixon JM, Jackson J, Hills M, Renshaw L, Cameron DA, Anderson TJ, Miller WR, Dowsett M: Anastrozole demonstrates clinical and biological effectiveness in oestrogen reception-positive breast cancers, irrespective of the erbB2 status. Eur J Cancer. 2004, 40: 2742-2747. 10.1016/j.ejca.2004.08.025.CrossRefPubMed Dixon JM, Jackson J, Hills M, Renshaw L, Cameron DA, Anderson TJ, Miller WR, Dowsett M: Anastrozole demonstrates clinical and biological effectiveness in oestrogen reception-positive breast cancers, irrespective of the erbB2 status. Eur J Cancer. 2004, 40: 2742-2747. 10.1016/j.ejca.2004.08.025.CrossRefPubMed
43.
Zurück zum Zitat Dowsett M, Harper-Wynne C, Boeddinghaus I, Salter J, Hills M, Dixon M, Ebbs S, Gui G, Sacks N, Smith I: HER-2 amplification impedes the antiproliferative effects of hormone therapy in estrogen receptor-positive primary breast cancer. Cancer Res. 2001, 61: 8452-8458.PubMed Dowsett M, Harper-Wynne C, Boeddinghaus I, Salter J, Hills M, Dixon M, Ebbs S, Gui G, Sacks N, Smith I: HER-2 amplification impedes the antiproliferative effects of hormone therapy in estrogen receptor-positive primary breast cancer. Cancer Res. 2001, 61: 8452-8458.PubMed
44.
Zurück zum Zitat Rasmussen BB, Regan MM, Lykkesfeldt AE, Dell'Orto P, Del Curto B, Henriksen KL, Mastropasqua MG, Price KN, Méry E, Lacroix-Triki M, Braye S, Altermatt HJ, Gelber RD, Castiglione-Gertsch M, Goldhirsch A, Gusterson BA, Thürlimann B, Coates AS, Viale G, BIG 1-98 Collaborative and International Breast Cancer Study Groups: Adjuvant letrozole versus tamoxifen according to centrally-assessed ERBB2 status for postmenopausal women with endocrine-responsive early breast cancer: supplementary results from the BIG 1-98 randomised trial. Lancet Oncol. 2008, 9: 23-28. 10.1016/S1470-2045(07)70386-8.CrossRefPubMed Rasmussen BB, Regan MM, Lykkesfeldt AE, Dell'Orto P, Del Curto B, Henriksen KL, Mastropasqua MG, Price KN, Méry E, Lacroix-Triki M, Braye S, Altermatt HJ, Gelber RD, Castiglione-Gertsch M, Goldhirsch A, Gusterson BA, Thürlimann B, Coates AS, Viale G, BIG 1-98 Collaborative and International Breast Cancer Study Groups: Adjuvant letrozole versus tamoxifen according to centrally-assessed ERBB2 status for postmenopausal women with endocrine-responsive early breast cancer: supplementary results from the BIG 1-98 randomised trial. Lancet Oncol. 2008, 9: 23-28. 10.1016/S1470-2045(07)70386-8.CrossRefPubMed
45.
Zurück zum Zitat Miller WR: ERBB2 status and outcome of endocrine treatment. Lancet Oncol. 2008, 9: 4-5. 10.1016/S1470-2045(07)70389-3.CrossRefPubMed Miller WR: ERBB2 status and outcome of endocrine treatment. Lancet Oncol. 2008, 9: 4-5. 10.1016/S1470-2045(07)70389-3.CrossRefPubMed
46.
Zurück zum Zitat Lal P, Tan LK, Chen B: Correlation of HER-2 status with estrogen and progesterone receptors and histologic features in 3,655 invasive breast carcinomas. Am J Clin Pathol. 2005, 123: 541-546. 10.1309/YMJ3A83TB39MRUT9.CrossRefPubMed Lal P, Tan LK, Chen B: Correlation of HER-2 status with estrogen and progesterone receptors and histologic features in 3,655 invasive breast carcinomas. Am J Clin Pathol. 2005, 123: 541-546. 10.1309/YMJ3A83TB39MRUT9.CrossRefPubMed
47.
Zurück zum Zitat Ma CX, Adjei AA, Salavaggione OE, Coronel J, Pelleymounter L, Wang L, Eckloff BW, Schaid D, Wieben ED, Adjei AA, Weinshilboum RM: Human aromatase: gene resequencing and functional genomics. Cancer Res. 2005, 65: 11071-11082. 10.1158/0008-5472.CAN-05-1218.CrossRefPubMed Ma CX, Adjei AA, Salavaggione OE, Coronel J, Pelleymounter L, Wang L, Eckloff BW, Schaid D, Wieben ED, Adjei AA, Weinshilboum RM: Human aromatase: gene resequencing and functional genomics. Cancer Res. 2005, 65: 11071-11082. 10.1158/0008-5472.CAN-05-1218.CrossRefPubMed
48.
Zurück zum Zitat Wang L, Ellsworth KA, Moon I, Pelleymounter LL, Eckloff BW, Martin YN, Fridley BL, Jenkins GD, Batzler A, Suman VJ, Ravi S, Dixon JM, Miller WR, Wieben ED, Buzdar A, Weinshilboum RM, Ingle JN: Functional genetic polymorphisms in the aromatase gene CYP19 vary the response of breast cancer patients to Neoadjuvant therapy with aromatase inhibitors. Cancer Res. 2010, 70: 319-328. 10.1158/0008-5472.CAN-09-3224.CrossRefPubMedPubMedCentral Wang L, Ellsworth KA, Moon I, Pelleymounter LL, Eckloff BW, Martin YN, Fridley BL, Jenkins GD, Batzler A, Suman VJ, Ravi S, Dixon JM, Miller WR, Wieben ED, Buzdar A, Weinshilboum RM, Ingle JN: Functional genetic polymorphisms in the aromatase gene CYP19 vary the response of breast cancer patients to Neoadjuvant therapy with aromatase inhibitors. Cancer Res. 2010, 70: 319-328. 10.1158/0008-5472.CAN-09-3224.CrossRefPubMedPubMedCentral
49.
Zurück zum Zitat Colomer R, Monzo M, Tusquets I, Rifa J, Baena JM, Barnadas A, Calvo L, Carabantes F, Crespo C, Muñoz M, Llombart A, Plazaola A, Artells R, Gilabert M, Lloveras B, Alba E: A single-nucleotide polymorphism in the aromatase gene is associated with the efficacy of the aromatase inhibitor letrozole in advanced breast carcinoma. Clin Cancer Res. 2008, 14: 811-816. 10.1158/1078-0432.CCR-07-1923.CrossRefPubMed Colomer R, Monzo M, Tusquets I, Rifa J, Baena JM, Barnadas A, Calvo L, Carabantes F, Crespo C, Muñoz M, Llombart A, Plazaola A, Artells R, Gilabert M, Lloveras B, Alba E: A single-nucleotide polymorphism in the aromatase gene is associated with the efficacy of the aromatase inhibitor letrozole in advanced breast carcinoma. Clin Cancer Res. 2008, 14: 811-816. 10.1158/1078-0432.CCR-07-1923.CrossRefPubMed
50.
Zurück zum Zitat Garcia-Casado Z, Guerrero-Zotano A, Llombart-Cussac A, Calatrava A, Fernandez-Serra A, Ruiz-Simon A, Gavila J, Climent MA, Almenar S, Cervera-Deval J, Campos J, Albaladejo CV, Llombart-Bosch A, Guillem V, Lopez-Guerrero JA: A polymorphism at the 3'-UTR region of the aromatase gene defines a subgroup of postmenopausal breast cancer patients with poor response to neoadjuvant letrozole. BMC Cancer. 2010, 10: 36-10.1186/1471-2407-10-36.CrossRefPubMedPubMedCentral Garcia-Casado Z, Guerrero-Zotano A, Llombart-Cussac A, Calatrava A, Fernandez-Serra A, Ruiz-Simon A, Gavila J, Climent MA, Almenar S, Cervera-Deval J, Campos J, Albaladejo CV, Llombart-Bosch A, Guillem V, Lopez-Guerrero JA: A polymorphism at the 3'-UTR region of the aromatase gene defines a subgroup of postmenopausal breast cancer patients with poor response to neoadjuvant letrozole. BMC Cancer. 2010, 10: 36-10.1186/1471-2407-10-36.CrossRefPubMedPubMedCentral
51.
Zurück zum Zitat Miller WR, Krause A, Larionov A, Evans DB, Anderson TJ, Dixon JM: Genes discriminating between breast cancers responsive or resistant to the aromatase inhibitor, letrozole. EJCMO. 2010, 2: 17-22. Miller WR, Krause A, Larionov A, Evans DB, Anderson TJ, Dixon JM: Genes discriminating between breast cancers responsive or resistant to the aromatase inhibitor, letrozole. EJCMO. 2010, 2: 17-22.
52.
Zurück zum Zitat Generali D, Buffa FM, Berruti A, Brizzi MP, Campo L, Bonardi S, Bersiga A, Allevi G, Milani M, Aguggini S, Papotti M, Dogliotti L, Bottini A, Harris AL, Fox SB: Phosphorylated ERalpha, HIF-1alpha, and MAPK signaling as predictors of primary endocrine treatment response and resistance in patients with breast cancer. J Clin Oncol. 2009, 27: 227-234. 10.1200/JCO.2007.13.7083.CrossRefPubMed Generali D, Buffa FM, Berruti A, Brizzi MP, Campo L, Bonardi S, Bersiga A, Allevi G, Milani M, Aguggini S, Papotti M, Dogliotti L, Bottini A, Harris AL, Fox SB: Phosphorylated ERalpha, HIF-1alpha, and MAPK signaling as predictors of primary endocrine treatment response and resistance in patients with breast cancer. J Clin Oncol. 2009, 27: 227-234. 10.1200/JCO.2007.13.7083.CrossRefPubMed
53.
Zurück zum Zitat Akli S, Bui T, Wingate H, Biernacka A, Moulder S, Tucker SL, Hunt KK, Keyomarsi K: Low-molecular-weight cyclin E can bypass letrozole-induced G1 arrest in human breast cancer cells and tumors. Clin Cancer Res. 2010, 16: 1179-1190. 10.1158/1078-0432.CCR-09-1787.CrossRefPubMedPubMedCentral Akli S, Bui T, Wingate H, Biernacka A, Moulder S, Tucker SL, Hunt KK, Keyomarsi K: Low-molecular-weight cyclin E can bypass letrozole-induced G1 arrest in human breast cancer cells and tumors. Clin Cancer Res. 2010, 16: 1179-1190. 10.1158/1078-0432.CCR-09-1787.CrossRefPubMedPubMedCentral
54.
Zurück zum Zitat Miller WR, Larionov A, Anderson TJ, Evans DB, Dixon JM: Sequential changes in gene expression profiles in breast cancers during treatment with the aromatase inhibitor, letrozole. Pharmacogenomics J. 2010, [Epub ahead of print] Miller WR, Larionov A, Anderson TJ, Evans DB, Dixon JM: Sequential changes in gene expression profiles in breast cancers during treatment with the aromatase inhibitor, letrozole. Pharmacogenomics J. 2010, [Epub ahead of print]
55.
Zurück zum Zitat Mello-Grand M, Singh V, Ghimenti C, Scatolini M, Regolo L, Grosso E, Zambelli A, Da Prada GA, Villani L, Fregoni V, Baiardi P, Marsoni S, Miller WR, Costa A, Chiorino G: Gene expression profiling and prediction of response to hormonal neoadjuvant treatment with anastrozole in surgically resectable breast cancer. Breast Cancer Res Treat. 2010, 121: 399-411. 10.1007/s10549-010-0887-y.CrossRefPubMed Mello-Grand M, Singh V, Ghimenti C, Scatolini M, Regolo L, Grosso E, Zambelli A, Da Prada GA, Villani L, Fregoni V, Baiardi P, Marsoni S, Miller WR, Costa A, Chiorino G: Gene expression profiling and prediction of response to hormonal neoadjuvant treatment with anastrozole in surgically resectable breast cancer. Breast Cancer Res Treat. 2010, 121: 399-411. 10.1007/s10549-010-0887-y.CrossRefPubMed
56.
Zurück zum Zitat Hauglid Flågeng M, Haugan Moi L L, Dixon J M, Geisler J, Lien E A, Miller W R, Lønning P E, Mellgren G: Nuclear receptor co-activators and HER-2/neu are upregulated in breast cancer patients during neo-adjuvant treatment with aromatase inhibitors. Br J Cancer. 2009, 101: 1253-1260. 10.1038/sj.bjc.6605324.CrossRefPubMedPubMedCentral Hauglid Flågeng M, Haugan Moi L L, Dixon J M, Geisler J, Lien E A, Miller W R, Lønning P E, Mellgren G: Nuclear receptor co-activators and HER-2/neu are upregulated in breast cancer patients during neo-adjuvant treatment with aromatase inhibitors. Br J Cancer. 2009, 101: 1253-1260. 10.1038/sj.bjc.6605324.CrossRefPubMedPubMedCentral
57.
Zurück zum Zitat Miller WR, Larionov A, Renshaw L, Anderson TJ, Walker JR, Krause A, Sing T, Evans DB, Dixon JM: Gene expression profiles differentiating between breast cancers clinically responsive or resistant to letrozole. J Clin Oncol. 2009, 27: 1382-1387. 10.1200/JCO.2008.16.8849.CrossRefPubMed Miller WR, Larionov A, Renshaw L, Anderson TJ, Walker JR, Krause A, Sing T, Evans DB, Dixon JM: Gene expression profiles differentiating between breast cancers clinically responsive or resistant to letrozole. J Clin Oncol. 2009, 27: 1382-1387. 10.1200/JCO.2008.16.8849.CrossRefPubMed
58.
Zurück zum Zitat Miller WR: Aromatase inhibitors: prediction of response and nature of resistance. Expert Opin Pharmacother. 2010, 11: 1873-1887. 10.1517/14656566.2010.487863.CrossRefPubMed Miller WR: Aromatase inhibitors: prediction of response and nature of resistance. Expert Opin Pharmacother. 2010, 11: 1873-1887. 10.1517/14656566.2010.487863.CrossRefPubMed
59.
Zurück zum Zitat Miller WR, Dixon JM: Local endocrine effects of aromatase inhibitors within the breast. J Steroid Biochem Mol Biol. 2001, 79: 93-102. 10.1016/S0960-0760(01)00148-0.CrossRefPubMed Miller WR, Dixon JM: Local endocrine effects of aromatase inhibitors within the breast. J Steroid Biochem Mol Biol. 2001, 79: 93-102. 10.1016/S0960-0760(01)00148-0.CrossRefPubMed
60.
Zurück zum Zitat Geisler J, Lønning PE: Endocrine effects of aromatase inhibitors and inactivators in vivo: review of data and method limitations. J Steroid Biochem Mol Biol. 2005, 95: 75-81. 10.1016/j.jsbmb.2005.04.015.CrossRefPubMed Geisler J, Lønning PE: Endocrine effects of aromatase inhibitors and inactivators in vivo: review of data and method limitations. J Steroid Biochem Mol Biol. 2005, 95: 75-81. 10.1016/j.jsbmb.2005.04.015.CrossRefPubMed
61.
Zurück zum Zitat Ingle JN: Pharmacogenetics and pharmacogenomics of endocrine agents for breast cancer. Breast Cancer Res. 2008, 10 (Suppl 4): S1-10.1186/bcr2161.CrossRef Ingle JN: Pharmacogenetics and pharmacogenomics of endocrine agents for breast cancer. Breast Cancer Res. 2008, 10 (Suppl 4): S1-10.1186/bcr2161.CrossRef
62.
Zurück zum Zitat Dowsett M, Pfi ster C, Johnston SR, Miles DW, Houston SJ, Verbeek JA, Gundacker H, Sioufi A, Smith IE: Impact of tamoxifen on the pharmacokinetics and endocrine effects of the aromatase inhibitor letrozole in postmenopausal women with breast cancer. Clin Cancer Res. 1999, 5: 2338-2343.PubMed Dowsett M, Pfi ster C, Johnston SR, Miles DW, Houston SJ, Verbeek JA, Gundacker H, Sioufi A, Smith IE: Impact of tamoxifen on the pharmacokinetics and endocrine effects of the aromatase inhibitor letrozole in postmenopausal women with breast cancer. Clin Cancer Res. 1999, 5: 2338-2343.PubMed
63.
Zurück zum Zitat ATAC Trialists Group: Pharmacokinetics of anastrozole and tamoxifen alone, and in combination, during adjuvant endocrine therapy for early breast cancer in postmenopausal women: sub-protocol of the 'Arimidex TM and Tamoxifen alone or in combination' (ATAC) trial. Br J Cancer. 2001, 85: 317-324. 10.1054/bjoc.2001.1925.CrossRef ATAC Trialists Group: Pharmacokinetics of anastrozole and tamoxifen alone, and in combination, during adjuvant endocrine therapy for early breast cancer in postmenopausal women: sub-protocol of the 'Arimidex TM and Tamoxifen alone or in combination' (ATAC) trial. Br J Cancer. 2001, 85: 317-324. 10.1054/bjoc.2001.1925.CrossRef
64.
Zurück zum Zitat Miller WR: Biological rationale for endocrine therapy in breast cancer. Best Pract Res Clin Endocrinol Metab. 2004, 18: 1-32. 10.1016/S1521-690X(03)00044-7.CrossRefPubMed Miller WR: Biological rationale for endocrine therapy in breast cancer. Best Pract Res Clin Endocrinol Metab. 2004, 18: 1-32. 10.1016/S1521-690X(03)00044-7.CrossRefPubMed
65.
Zurück zum Zitat Sourdaine P, Parker MG, Telford J, Miller WR: Analysis of the aromatase cytochrome P450 gene in human breast cancers. J Mol Endocrinol. 1994, 13: 331-337. 10.1677/jme.0.0130331.CrossRefPubMed Sourdaine P, Parker MG, Telford J, Miller WR: Analysis of the aromatase cytochrome P450 gene in human breast cancers. J Mol Endocrinol. 1994, 13: 331-337. 10.1677/jme.0.0130331.CrossRefPubMed
66.
Zurück zum Zitat ATAC (Arimidex, Tamoxifen Alone or in Combination) Trialists Group: Anastrozole alone or in combination with versus tamoxifen alone for adjuvant treatment of postmenopausal women with early breast cancer: first results of the ATAC randomised trial. Lancet. 2002, 359: 2131-2139.CrossRef ATAC (Arimidex, Tamoxifen Alone or in Combination) Trialists Group: Anastrozole alone or in combination with versus tamoxifen alone for adjuvant treatment of postmenopausal women with early breast cancer: first results of the ATAC randomised trial. Lancet. 2002, 359: 2131-2139.CrossRef
67.
Zurück zum Zitat MacGregor JI, Jordan VC: Basic guide to the mechanisms of antiestrogen action. Pharmacol Rev. 1998, 50: 151-196.PubMed MacGregor JI, Jordan VC: Basic guide to the mechanisms of antiestrogen action. Pharmacol Rev. 1998, 50: 151-196.PubMed
68.
Zurück zum Zitat Makris A, Powles TJ, Allred DC, Ashley S, Ormerod MG, Titley JC, Dowsett M: Changes in hormone receptors and proliferation markers in tamoxifen treated breast cancer patients and the relationship with response. Breast Cancer Res Treat. 1998, 48: 11-20. 10.1023/A:1005973529921.CrossRefPubMed Makris A, Powles TJ, Allred DC, Ashley S, Ormerod MG, Titley JC, Dowsett M: Changes in hormone receptors and proliferation markers in tamoxifen treated breast cancer patients and the relationship with response. Breast Cancer Res Treat. 1998, 48: 11-20. 10.1023/A:1005973529921.CrossRefPubMed
69.
Zurück zum Zitat Miller WR, Dixon JM, Macfarlane L, Cameron D, Anderson TJ: Pathological features of breast cancer response following neoadjuvant treatment with either letrozole or tamoxifen. Eur J Cancer. 2003, 39: 462-468. 10.1016/S0959-8049(02)00600-7.CrossRefPubMed Miller WR, Dixon JM, Macfarlane L, Cameron D, Anderson TJ: Pathological features of breast cancer response following neoadjuvant treatment with either letrozole or tamoxifen. Eur J Cancer. 2003, 39: 462-468. 10.1016/S0959-8049(02)00600-7.CrossRefPubMed
71.
Zurück zum Zitat Johnston SRD, Dowsett M: Aromatase inhibitors for breast cancer: lessons from the laboratory. Nat Rev Cancer. 2003, 3: 821-831. 10.1038/nrc1211.CrossRefPubMed Johnston SRD, Dowsett M: Aromatase inhibitors for breast cancer: lessons from the laboratory. Nat Rev Cancer. 2003, 3: 821-831. 10.1038/nrc1211.CrossRefPubMed
72.
Zurück zum Zitat Fuqua SA, Cui Y: Estrogen and progesterone receptor isoforms: clinical significance in breast cancer. Breast Cancer Res Treat. 2004, 87 (Suppl 1): S3-10.CrossRefPubMed Fuqua SA, Cui Y: Estrogen and progesterone receptor isoforms: clinical significance in breast cancer. Breast Cancer Res Treat. 2004, 87 (Suppl 1): S3-10.CrossRefPubMed
73.
Zurück zum Zitat Mayordomo J, Llombart A, Martín M, Antón A, Barnadas A, Antolín S, Alés-Martínez J, Álvarez I: Randomized, multicenter, crossover phase II trial to compare exemestane (E) vs. anastrozole (A) in postmenopausal patients (pt) with advanced breast cancer (ABC) and positive hormone receptors (HR). Final efficacy analysis of GEICAM 2001-03 study. J Clin Oncol. 2006, 24 (Suppl): 638- Mayordomo J, Llombart A, Martín M, Antón A, Barnadas A, Antolín S, Alés-Martínez J, Álvarez I: Randomized, multicenter, crossover phase II trial to compare exemestane (E) vs. anastrozole (A) in postmenopausal patients (pt) with advanced breast cancer (ABC) and positive hormone receptors (HR). Final efficacy analysis of GEICAM 2001-03 study. J Clin Oncol. 2006, 24 (Suppl): 638-
74.
Zurück zum Zitat Iaffaioli RV, Formato R, Tortoriello A, Del Prete S, Caraglia M, Pappagallo G, Pisano A, Gebbia V, Fanelli F, Ianniello G, Cigolari S, Pizza C, Marano O, Pezzella G, Pedicini T, Febbraro A, Incoronato P, Manzione L, Ferrari E, Marzano N, Quattrin S, Pisconti S, Nasti G, Giotta G, Colucci G, Southern Italy Oncology Group: Phase II study of sequential hormonal therapy with anastrozole/exemestane in advanced and metastatic breast cancer. Br J Cancer. 2005, 92: 1621-1625. 10.1038/sj.bjc.6602579.CrossRefPubMedPubMedCentral Iaffaioli RV, Formato R, Tortoriello A, Del Prete S, Caraglia M, Pappagallo G, Pisano A, Gebbia V, Fanelli F, Ianniello G, Cigolari S, Pizza C, Marano O, Pezzella G, Pedicini T, Febbraro A, Incoronato P, Manzione L, Ferrari E, Marzano N, Quattrin S, Pisconti S, Nasti G, Giotta G, Colucci G, Southern Italy Oncology Group: Phase II study of sequential hormonal therapy with anastrozole/exemestane in advanced and metastatic breast cancer. Br J Cancer. 2005, 92: 1621-1625. 10.1038/sj.bjc.6602579.CrossRefPubMedPubMedCentral
75.
Zurück zum Zitat Steele N, Zekri J, Coleman R, Leonard R, Dunn K, Bowman A, Manifold I, Kunkler I, Purohit O, Cameron D: Exemestane in metastatic breast cancer: effective therapy after third-generation non-steroidal aromatase inhibitor failure. Breast. 2006, 15: 430-436.CrossRefPubMed Steele N, Zekri J, Coleman R, Leonard R, Dunn K, Bowman A, Manifold I, Kunkler I, Purohit O, Cameron D: Exemestane in metastatic breast cancer: effective therapy after third-generation non-steroidal aromatase inhibitor failure. Breast. 2006, 15: 430-436.CrossRefPubMed
76.
Zurück zum Zitat Chin YS, Beresford MJ, Ravichandran D, Makris A: Exemestane after non-steroidal aromatase inhibitors for post-menopausal women with advanced breast cancer. Breast. 2007, 16: 436-439. 10.1016/j.breast.2007.02.002.CrossRefPubMed Chin YS, Beresford MJ, Ravichandran D, Makris A: Exemestane after non-steroidal aromatase inhibitors for post-menopausal women with advanced breast cancer. Breast. 2007, 16: 436-439. 10.1016/j.breast.2007.02.002.CrossRefPubMed
77.
Zurück zum Zitat Carlini P, Michelotti A, Ferretti G, Ricci S, Giannarelli D, Pellegrini M, Cresti N, Di Cosimo S, Bria E, Papaldo P, Fabi A, Ruggeri EM, Milella M, Alimonti A, Salesi N, Cognetti F: Clinical evaluation of the use of exemestane as further hormonal therapy after nonsteroidal aromatase inhibitors in postmenopausal metastatic breast cancer patients. Cancer Invest. 2007, 25: 102-105. 10.1080/07357900701224789.CrossRefPubMed Carlini P, Michelotti A, Ferretti G, Ricci S, Giannarelli D, Pellegrini M, Cresti N, Di Cosimo S, Bria E, Papaldo P, Fabi A, Ruggeri EM, Milella M, Alimonti A, Salesi N, Cognetti F: Clinical evaluation of the use of exemestane as further hormonal therapy after nonsteroidal aromatase inhibitors in postmenopausal metastatic breast cancer patients. Cancer Invest. 2007, 25: 102-105. 10.1080/07357900701224789.CrossRefPubMed
78.
Zurück zum Zitat Gennatas C, Michalaki V, Carvounis E, Psychogios J, Poulakaki N, Katsiamis G, Voros D, Kouloulias V, Mouratidou D, Tsavaris N: Third-line hormonal treatment with exemestane in postmenopausal patients with advanced breast cancer progressing on letrozole or anastrozole. A phase II trial conducted by the Hellenic Group of Oncology (HELGO). Tumori. 2006, 92: 13-17.PubMed Gennatas C, Michalaki V, Carvounis E, Psychogios J, Poulakaki N, Katsiamis G, Voros D, Kouloulias V, Mouratidou D, Tsavaris N: Third-line hormonal treatment with exemestane in postmenopausal patients with advanced breast cancer progressing on letrozole or anastrozole. A phase II trial conducted by the Hellenic Group of Oncology (HELGO). Tumori. 2006, 92: 13-17.PubMed
Metadaten
Titel
Understanding the mechanisms of aromatase inhibitor resistance
verfasst von
William R Miller
Alexey A Larionov
Publikationsdatum
01.02.2012
Verlag
BioMed Central
Erschienen in
Breast Cancer Research / Ausgabe 1/2012
Elektronische ISSN: 1465-542X
DOI
https://doi.org/10.1186/bcr2931

Weitere Artikel der Ausgabe 1/2012

Breast Cancer Research 1/2012 Zur Ausgabe

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.